{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2011"],"condition":["Colorectal cancer","resectable liver metastases of colorectal carcinoma with proven K-RAS wildtype"],"disease":["Resectable Liver Metastases Of Colorectal Carcinoma With Proven K-ras Wildtype","Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2525125"],"location":["Austria","Germany"],"study_start_month":["5"],"keyword":["Oxaliplatin","5-Fluorouracil","Cetuximab","Folinsäure"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Perioperative chemotherapy with FOLFOX plus Cetuximab versus adjuvant FOLFOX plus Cetuximab for patients with resectable liver metastases of colorectal carcinoma","description":"Primary objectives: The first primary objective of the study is to compare the postoperative complication rate according to Clavien score (> grade 1) of a perioperative chemotherapy with a postoperative regimen. A second primary objective of the study is to compare for the patient subgroup with >3 liver metastases or at least one metastasis ≥ 5 cm in diameter the median disease free survival.\nPrimary endpoints: The first primary objective of the study is to compare the postoperative complication rate according to the Clavien score (> grade 1) (Appendix 2) of a perioperative chemotherapy with a postoperative regimen. A second primary objective of the study is to compare for the patient subgroup with > 3 liver metastases or at least one metastasis ≥ 5 cm in diameter the median disease free survival between the two treatment arms","dates":{"creation":"2011-05-15"},"accession":"2525125","cross_references":{"EU Clinical Trials Register":["2008-005312-41"]}}